Compass Therapeutics, Inc. (CMPX) Stock Overview
Explore Compass Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Compass Therapeutics, Inc. (CMPX)
Key Financials
Key Financials
Market Cap
374.6M
P/E Ratio
-5.00
EPS (TTM)
$-0.41
ROE
-0.40%
CMPX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Compass Therapeutics, Inc. (NASDAQ: CMPX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Compass Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CMPX on the NASDAQ shows an RSI of 49.69, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $5.42 for the NASDAQ listing.
Key metrics behind Compass Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -5.00 and a market capitalization of 374.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CMPX on the NASDAQ.